We are live on ! Find out more
DYN icon

Dyne Therapeutics
DYN

127 hedge funds and large institutions have $629M invested in Dyne Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 54 increasing their positions, 30 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

3,420% more call options, than puts

Call options by funds: $176K | Put options by funds: $5K

233% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 6

80% more repeat investments, than reductions

Existing positions increased: 54 | Existing positions reduced: 30

12% more funds holding

Funds holding: 113 → 127 (+14)

10% more capital invested

Capital invested by funds: $571M → $629M (+$57.8M)

1.58% more ownership

Funds ownership: 95.38% → 96.96% (+1.6%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
127
Holders Change
+14
Holders Change %
+12.39%
% of All Funds
2.02%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
20
Increased
54
Reduced
30
Closed
6
Calls
$176K
Puts
$5K
Net Calls
+$171K
Net Calls Change
-$640K

Top Buyers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
+$21.4M
2
OCA
Octagon Capital Advisors
New York
+$9M
3
Goldman Sachs
Goldman Sachs
New York
+$8.55M
4
B
Braidwell
Connecticut
+$8.11M
5
WA
Wasatch Advisors
Utah
+$5.29M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6.06M
2
HA
HHLR Advisors
Cayman Islands
-$5.99M
3
LGM
Logos Global Management
California
-$5.84M
4
DTC
Deep Track Capital
Connecticut
-$4.54M
5
IBT
International Biotechnology Trust
United Kingdom
-$2.69M
Name Holding Trade Value Shares
Change 		Change in
Stake
IBT
26
International Biotechnology Trust
United Kingdom
$4.99M -$2.69M -207,317 -32%
Axa
27
Axa
France
$4.89M +$719K +55,328 +15%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$4.71M -$2.14M -165,064 -29%
Norges Bank
29
Norges Bank
Norway
$4.19M +$2.67M +205,848 +130%
AllianceBernstein
30
AllianceBernstein
Tennessee
$3.78M +$176K +13,524 +4%
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$3.36M +$3.28M +252,232 +645%
ACH
32
ArrowMark Colorado Holdings
Colorado
$3.17M – – –
Northern Trust
33
Northern Trust
Illinois
$3.16M -$85.2K -6,562 -2%
Federated Hermes
34
Federated Hermes
Pennsylvania
$3.03M +$3.42M +262,960 +111,424%
Invesco
35
Invesco
Georgia
$2.78M +$1.38M +106,116 +79%
Two Sigma Advisers
36
Two Sigma Advisers
New York
$2.72M +$1.68M +129,200 +120%
Jacobs Levy Equity Management
37
Jacobs Levy Equity Management
New Jersey
$2.64M -$794K -61,172 -21%
Charles Schwab
38
Charles Schwab
California
$2.62M -$7.25K -558 -0.2%
Ensign Peak Advisors
39
Ensign Peak Advisors
Utah
$2.61M +$2.42M +186,626 +467%
SFM
40
Sphera Funds Management
Israel
$2.53M +$2.76M +212,167 +2,968%
AG
41
Algert Global
California
$2.21M +$496K +38,227 +25%
Millennium Management
42
Millennium Management
New York
$2.19M -$828K -63,747 -25%
NCM
43
Nantahala Capital Management
Connecticut
$2.06M +$2.32M +178,901 New
UOC
44
UBS O'Connor
Illinois
$2.03M +$2.29M +176,601 New
Two Sigma Investments
45
Two Sigma Investments
New York
$1.83M +$47.2K +3,638 +2%
ACM
46
Altium Capital Management
New York
$1.79M +$2.01M +155,000 New
N
47
Nuveen
North Carolina
$1.55M -$145K -11,168 -8%
Marshall Wace
48
Marshall Wace
United Kingdom
$1.52M +$1.43M +110,292 +500%
Bank of New York Mellon
49
Bank of New York Mellon
New York
$1.46M -$5.61K -432 -0.3%
Morgan Stanley
50
Morgan Stanley
New York
$1.31M +$639K +49,200 +76%
1
2
3 4 5

DYN Hedge Fund Activity: Q1 2023 in Review

127 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2023, worth a combined $629M — up 10% from $571M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new DYN positions and 6 closed out — a net gain of 14 holders — while 54 added to existing stakes and 30 trimmed.

The largest buyer was TCG Crossover Management, opening a new position worth an estimated $21.4M. The largest seller was Point72 Asset Management, cutting an estimated $6.06M.

  • 127 institutional investors held Dyne Therapeutics (DYN) as of Q1 2023, up from 113 in Q4 2022.
  • Funds reported $629M of Dyne Therapeutics stock for Q1 2023, up 10% quarter-over-quarter.
  • 20 funds opened new Dyne Therapeutics positions in Q1 2023 and 6 closed out, a net change of +14 holders.
  • The largest Dyne Therapeutics buyer in Q1 2023 was TCG Crossover Management, an estimated $21.4M added.
  • The largest Dyne Therapeutics seller in Q1 2023 was Point72 Asset Management, an estimated $6.06M sold.

Based on aggregated 13F filings for Q1 2023.